October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to ...
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Results from a prospective randomized trial of transradial (TRI) versus transfemoral (TFO) access in patients undergoing percutaneous coronary intervention found that TRI was non-inferior in terms of clinical effectiveness at one year and superior in reducing major bleeding complications at seven days compared to TFI.
New results from a multicenter, prospective study show that assessing fractional flow reserve estimated with computed tomography (FFR-CT) may reduce costs in selected symptomatic patients with suspected coronary artery disease (CAD).
Two-year results from the IN.PACT SFA study found the use of a drug-coated balloon was superior to conventional percutaneous transluminal angioplasty (PTA) in treating patients with superficial femoral artery (SFA) disease.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The main pumping chamber of the heart ages differently in men and women, according to a new magnetic resonance imaging (MRI) study published online in the journal Radiology. Researchers said the findings may support different treatment approaches for men and women with heart disease.
Long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent cryptogenic stroke in patients who had previously experienced one.
October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
October 14, 2015 — Claret Medical, an innovator in cardiovascular cerebral protection, Data presented this week at ...
Results from a clinical trial showed that an everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to a current generation metallic drug-eluting stent (DES) in patients with coronary artery disease. Target lesion failure (TLF) was the primary endpoint for the study.
Edwards Lifesciences Corp. announced that details on the 13 first-in-human compassionate use cases with its Forma transcatheter tricuspid repair system were presented at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. The results of the first seven cases were also published online this week in the Journal of the American College of Cardiology.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients.
One-year patient outcomes from the PARTNER II trial showed the low rate of 30-day complications with balloon-expandable transcatheter aortic valve replacement (TAVR) in high-risk and inoperable patients with aortic stenosis persisted with follow-up to one year.
October 15, 2015 — U.S. Food and Drug Administration (FDA) has cleared Edwards Lifesciences Sapien XT transcatheter ...